CA3166331A1 - Salts and crystalline forms of a taar1 agonist - Google Patents
Salts and crystalline forms of a taar1 agonistInfo
- Publication number
- CA3166331A1 CA3166331A1 CA3166331A CA3166331A CA3166331A1 CA 3166331 A1 CA3166331 A1 CA 3166331A1 CA 3166331 A CA3166331 A CA 3166331A CA 3166331 A CA3166331 A CA 3166331A CA 3166331 A1 CA3166331 A1 CA 3166331A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrochloric acid
- disorders
- acid salt
- methyl
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20164069 | 2020-03-19 | ||
| EP20164069.5 | 2020-03-19 | ||
| PCT/EP2021/056749 WO2021185878A1 (en) | 2020-03-19 | 2021-03-17 | Salts and crystalline forms of a taar1 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3166331A1 true CA3166331A1 (en) | 2021-09-23 |
Family
ID=69846246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3166331A Pending CA3166331A1 (en) | 2020-03-19 | 2021-03-17 | Salts and crystalline forms of a taar1 agonist |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230120311A1 (https=) |
| EP (1) | EP4121428B1 (https=) |
| JP (2) | JP2023517729A (https=) |
| KR (1) | KR20220155575A (https=) |
| CN (1) | CN115279752A (https=) |
| AU (1) | AU2021238632A1 (https=) |
| BR (1) | BR112022016746A2 (https=) |
| CA (1) | CA3166331A1 (https=) |
| ES (1) | ES3044409T3 (https=) |
| IL (1) | IL294301A (https=) |
| MX (1) | MX2022010794A (https=) |
| TW (1) | TWI874616B (https=) |
| WO (1) | WO2021185878A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023323858A1 (en) * | 2022-08-12 | 2024-11-21 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide |
| WO2024222860A1 (zh) * | 2023-04-28 | 2024-10-31 | 江苏豪森药业集团有限公司 | 一种吗啉杂环类化合物的盐及其制备方法和应用 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO2017157873A1 (en) * | 2016-03-17 | 2017-09-21 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
-
2021
- 2021-03-17 EP EP21712158.1A patent/EP4121428B1/en active Active
- 2021-03-17 WO PCT/EP2021/056749 patent/WO2021185878A1/en not_active Ceased
- 2021-03-17 ES ES21712158T patent/ES3044409T3/es active Active
- 2021-03-17 TW TW110109520A patent/TWI874616B/zh active
- 2021-03-17 JP JP2022555821A patent/JP2023517729A/ja active Pending
- 2021-03-17 CN CN202180017438.9A patent/CN115279752A/zh active Pending
- 2021-03-17 AU AU2021238632A patent/AU2021238632A1/en active Pending
- 2021-03-17 BR BR112022016746A patent/BR112022016746A2/pt unknown
- 2021-03-17 MX MX2022010794A patent/MX2022010794A/es unknown
- 2021-03-17 IL IL294301A patent/IL294301A/en unknown
- 2021-03-17 CA CA3166331A patent/CA3166331A1/en active Pending
- 2021-03-17 KR KR1020227031814A patent/KR20220155575A/ko active Pending
-
2022
- 2022-09-16 US US17/946,743 patent/US20230120311A1/en active Pending
-
2025
- 2025-08-07 JP JP2025132332A patent/JP2025166092A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023517729A (ja) | 2023-04-26 |
| EP4121428A1 (en) | 2023-01-25 |
| BR112022016746A2 (pt) | 2022-10-11 |
| WO2021185878A1 (en) | 2021-09-23 |
| KR20220155575A (ko) | 2022-11-23 |
| US20230120311A1 (en) | 2023-04-20 |
| EP4121428B1 (en) | 2025-08-13 |
| IL294301A (en) | 2022-08-01 |
| AU2021238632A1 (en) | 2022-07-14 |
| TW202140466A (zh) | 2021-11-01 |
| ES3044409T3 (en) | 2025-11-26 |
| EP4121428C0 (en) | 2025-08-13 |
| TWI874616B (zh) | 2025-03-01 |
| CN115279752A (zh) | 2022-11-01 |
| MX2022010794A (es) | 2022-09-27 |
| JP2025166092A (ja) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230120311A1 (en) | Salts and crystalline forms of a taar1 agonist | |
| CN103958469B (zh) | 一种新的普利多匹定盐酸盐多晶型形态 | |
| JP6995043B2 (ja) | リジン特異的デメチラーゼ－１の阻害剤を含む組成物 | |
| EP4261212A1 (en) | Crystal form of tolebrutinib, preparation method therefor and use thereof | |
| AU2016279075B2 (en) | Crystalline compounds | |
| AU2018303293B2 (en) | Amorphous form of vilanterol trifenatate and processes for the preparation thereof | |
| JP5997162B2 (ja) | アプレピタントｌ−プロリン組成物および共結晶 | |
| US20230322657A1 (en) | Crystalline edg-2 receptor antagonist and methods of making | |
| HK40074347A (en) | Salts and crystalline forms of a taar1 agonist | |
| US20130150450A1 (en) | Novel solid forms of tacedinaline | |
| EP4553078A1 (en) | 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof | |
| TW202506661A (zh) | 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法 | |
| HK40077679A (en) | Crystalline compounds | |
| JP2025527600A (ja) | グルコシルセラミド合成酵素阻害薬の結晶形及びその使用 | |
| CA3255634A1 (en) | Crystalline forms of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1h,2h,3h,4h,5h-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one and salts thereof, method of preparation, and uses thereof | |
| WO2018130226A1 (zh) | 利奥西呱的新晶型及其制备方法和用途 | |
| HK40003818A (en) | Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof | |
| HK1187554B (en) | Aprepitant l-proline composition and cocrystal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250225 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250305 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250305 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250317 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250512 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251006 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260313 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260313 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260407 |